[go: up one dir, main page]

IT1395963B1 - Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali - Google Patents

Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali

Info

Publication number
IT1395963B1
IT1395963B1 ITTO2009A000424A ITTO20090424A IT1395963B1 IT 1395963 B1 IT1395963 B1 IT 1395963B1 IT TO2009A000424 A ITTO2009A000424 A IT TO2009A000424A IT TO20090424 A ITTO20090424 A IT TO20090424A IT 1395963 B1 IT1395963 B1 IT 1395963B1
Authority
IT
Italy
Prior art keywords
chinazolin
fenyl
imidazol
salts
crystalline forms
Prior art date
Application number
ITTO2009A000424A
Other languages
English (en)
Inventor
Lucio Claudio Rovati
Matteo Ghirri
Antonio Giordani
Stefano Mandelli
Francesca Porta
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41527692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1395963(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Priority to ITTO2009A000424A priority Critical patent/IT1395963B1/it
Priority to CN201080024845.4A priority patent/CN102459237B/zh
Priority to AU2010255376A priority patent/AU2010255376A1/en
Priority to KR1020167022691A priority patent/KR101939145B1/ko
Priority to RU2011153981/04A priority patent/RU2557547C2/ru
Priority to KR1020127000282A priority patent/KR20120028362A/ko
Priority to JP2012513729A priority patent/JP5739879B2/ja
Priority to PCT/IB2010/052496 priority patent/WO2010140139A2/en
Priority to ES10731576.4T priority patent/ES2676646T3/es
Priority to HUE10731576A priority patent/HUE037631T2/hu
Priority to BRPI1009006-1A priority patent/BRPI1009006B1/pt
Priority to US13/375,816 priority patent/US9174966B2/en
Priority to CA2762307A priority patent/CA2762307C/en
Priority to EP10731576.4A priority patent/EP2438058B1/en
Priority to MX2011012859A priority patent/MX343234B/es
Priority to DK10731576.4T priority patent/DK2438058T3/en
Publication of ITTO20090424A1 publication Critical patent/ITTO20090424A1/it
Publication of IT1395963B1 publication Critical patent/IT1395963B1/it
Application granted granted Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/541,3-Diazines; Hydrogenated 1,3-diazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ITTO2009A000424A 2009-06-04 2009-06-04 Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali IT1395963B1 (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ITTO2009A000424A IT1395963B1 (it) 2009-06-04 2009-06-04 Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
ES10731576.4T ES2676646T3 (es) 2009-06-04 2010-06-04 Formas cristalinas de 6-(1H-imidazol-1-il)-2-fenilquinazolina
BRPI1009006-1A BRPI1009006B1 (pt) 2009-06-04 2010-06-04 Forma Polimórfica de 6-(1H-imidazol-1-il)-2-fenil-quinazolina, seu processo de preparação, formulação e composição farmacêutica
KR1020167022691A KR101939145B1 (ko) 2009-06-04 2010-06-04 6―(1h―이미다졸―1―일)―2―페닐퀴나졸린의 결정 형태
RU2011153981/04A RU2557547C2 (ru) 2009-06-04 2010-06-04 Кристаллические формы 6-(1н-имидазол-1-ил)-2-фенилхиназолина и его солей
KR1020127000282A KR20120028362A (ko) 2009-06-04 2010-06-04 6?(1h?이미다졸?1?일)?2?페닐퀴나졸린의 결정 형태
JP2012513729A JP5739879B2 (ja) 2009-06-04 2010-06-04 6−(1h−イミダゾール−1−イル)−2−フェニルキナゾリンおよびその塩の結晶形
PCT/IB2010/052496 WO2010140139A2 (en) 2009-06-04 2010-06-04 Crystalline forms of 6- ( 1h- imidazol- 1-yl) -2-phenylquinazoline and salts thereof
CN201080024845.4A CN102459237B (zh) 2009-06-04 2010-06-04 6-(1h-咪唑-1-基)-2-苯基喹唑啉的晶型
HUE10731576A HUE037631T2 (hu) 2009-06-04 2010-06-04 A 6-(1H-imidazol-1-il)-2-fenil-kinazolin kristályformái
AU2010255376A AU2010255376A1 (en) 2009-06-04 2010-06-04 Crystalline forms of 6-(1H- imadazol- 1-yl) -2-phenylquinazoline
US13/375,816 US9174966B2 (en) 2009-06-04 2010-06-04 Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline
CA2762307A CA2762307C (en) 2009-06-04 2010-06-04 Crystalline forms of 6-(1h-imidazol-1-yl)-2-phenylquinazoline and salts thereof.
EP10731576.4A EP2438058B1 (en) 2009-06-04 2010-06-04 Crystalline forms of 6-(1h-imidazol-1-yl)-2-phenylquinazoline
MX2011012859A MX343234B (es) 2009-06-04 2010-06-04 Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
DK10731576.4T DK2438058T3 (en) 2009-06-04 2010-06-04 CRYSTALLINIC FORMS OF 6- (1H-IMIDAZOL-1-YL) -2-PHENYLQUINAZOLINE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITTO2009A000424A IT1395963B1 (it) 2009-06-04 2009-06-04 Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali

Publications (2)

Publication Number Publication Date
ITTO20090424A1 ITTO20090424A1 (it) 2010-12-05
IT1395963B1 true IT1395963B1 (it) 2012-11-02

Family

ID=41527692

Family Applications (1)

Application Number Title Priority Date Filing Date
ITTO2009A000424A IT1395963B1 (it) 2009-06-04 2009-06-04 Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali

Country Status (15)

Country Link
US (1) US9174966B2 (it)
EP (1) EP2438058B1 (it)
JP (1) JP5739879B2 (it)
KR (2) KR101939145B1 (it)
CN (1) CN102459237B (it)
AU (1) AU2010255376A1 (it)
BR (1) BRPI1009006B1 (it)
CA (1) CA2762307C (it)
DK (1) DK2438058T3 (it)
ES (1) ES2676646T3 (it)
HU (1) HUE037631T2 (it)
IT (1) IT1395963B1 (it)
MX (1) MX343234B (it)
RU (1) RU2557547C2 (it)
WO (1) WO2010140139A2 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20120103A1 (it) * 2012-02-08 2013-08-09 Rottapharm Spa Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
ITTO20120102A1 (it) * 2012-02-08 2013-08-09 Rottapharm Spa Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
MX373874B (es) * 2013-03-06 2020-03-26 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
JP6961348B2 (ja) * 2014-04-22 2021-11-05 アークル インコーポレイテッド 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
EP3822264A4 (en) * 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
EP3735974A1 (en) 2019-05-10 2020-11-11 Rottapharm Biotech S.r.l. Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
TWI866977B (zh) * 2019-06-03 2024-12-21 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 吡唑化合物之非吸濕性結晶鹽及其醫藥組合物及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2066653T3 (pl) * 2006-08-03 2013-02-28 Rottapharm Biotech Srl Pochodne 6-1H-imidazo-chinazoliny i chinoliny, nowe silne środki przeciwbólowe i przeciwzapalne
US8999590B2 (en) * 2007-07-25 2015-04-07 Fuelcell Energy, Inc. On-line monitoring assembly for detection of sulfur breakthrough in a desulfurizer assembly and sulfur breakthrough detection method
PT2315588E (pt) * 2008-06-20 2013-03-25 Rottapharm Spa Derivados de 6-1h-imidazo-quinazolina e quinolinas, novos inibidores de mao e ligandos de receptores de imidazolinas

Also Published As

Publication number Publication date
KR101939145B1 (ko) 2019-01-16
ES2676646T3 (es) 2018-07-23
JP5739879B2 (ja) 2015-06-24
BRPI1009006B1 (pt) 2019-09-24
AU2010255376A1 (en) 2011-12-01
KR20120028362A (ko) 2012-03-22
WO2010140139A3 (en) 2011-01-27
CA2762307A1 (en) 2010-12-09
CN102459237B (zh) 2015-05-27
RU2011153981A (ru) 2013-07-20
US9174966B2 (en) 2015-11-03
BRPI1009006A2 (pt) 2016-03-08
MX2011012859A (es) 2012-05-23
JP2012528849A (ja) 2012-11-15
RU2557547C2 (ru) 2015-07-27
EP2438058A2 (en) 2012-04-11
ITTO20090424A1 (it) 2010-12-05
HUE037631T2 (hu) 2018-09-28
US20120142713A1 (en) 2012-06-07
CA2762307C (en) 2017-12-12
DK2438058T3 (en) 2018-06-06
MX343234B (es) 2016-10-27
EP2438058B1 (en) 2018-04-11
CN102459237A (zh) 2012-05-16
WO2010140139A2 (en) 2010-12-09
KR20160102325A (ko) 2016-08-29

Similar Documents

Publication Publication Date Title
IL283935A (en) An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
BRPI0915714A2 (pt) forma cristalina de posaconazol
IL226477A (en) Salts and polymorphic forms of Aptinib
EP2580225A4 (en) BENZYL BENZENOL SGLT2 HEMMER CRYSTALLINE FORM
IL210322A0 (en) Crystalline salts of sitagliptin
ZA201303586B (en) Salts and crystalline forms of an apoptosis-inducing agent
EP2742051A4 (en) AMORPHIC FORM OF DOLUTEGRAVIR
IL215472A0 (en) Salt of abt-263 and solid-state forms thereof
EP2455379A4 (en) CRYSTALS OF SODIUM SALTS OF PYRROLOQUINOLINEINQUINONE
SMT201900049T1 (it) Composti eterociclici e loro utilizzi
FR22C1023I1 (fr) Forme polymorphe st-246 et procedes de preparation
SMT201300063B (it) Procedimento per preparazione di composti piperazinici e loro sali idrocloruri
BRPI1011046A2 (pt) derivados de isoquinolin-1 (2h)-ona como inibidores de parp-i
IT1395963B1 (it) Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
IL215315A0 (en) Solid state forms of sitagliptin salts
IT1392813B1 (it) Forme cristalline di dexlansoprazolo
FI20096012A0 (fi) Menetelmä ja järjestely kiteisten rakenteiden tuottamiseksi
BRPI1008007A2 (pt) derivados de piridazinona substituídos por heteroarila
EP2938607A4 (en) SALTS AND CRYSTALLINE FORMS
DK2307397T3 (da) 6-substituerede phenoxychroman-carboxylsyrederivater
EP2265586A4 (en) PREPARATION OF MONTELUKAST AND ITS SALTS
IL209837A0 (en) Sulfonate salts of flupirtine
BRPI1013552A2 (pt) retenção para linha de controle e método para reter linha de controle
IL219935A0 (en) Small pyrimidine derivatives and methods of use thereof
IT1395118B1 (it) Procedimento per la preparazione di dexlansoprazolo cristallino